logo-loader
Redx Pharma Plc

New Redx CEO bringing leadership and skills to 'capitalise on its great science'

Lisa Anson, the new chief executive at Redx Pharma Plc (LON:REDX), sat down with Proactive's Andrew Scott just weeks after taking on the new role.

Anson was the president of AstraZeneca PLC’s (LON:AZN) UK division immediately prior to joining, while she's also held various other senior leadership roles during her 20-year career at the FTSE 100-drugs giant.

The first patient in a Phase I/II trial for Redx's lead drug RXC004 was dosed back in February but they paused the study just over a month later, admitting that the dosing levels it had thought were right based on pre-clinical research were actually too high.

Since then it has been talking with regulators about lowering the dose and getting the trial back up and running again which it expects will happen in the first half of 2019.

Quick facts: Redx Pharma Plc

Price: £0.09

Market: AIM
Market Cap: £11.7 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Redx Pharma Plc named herein, including the promotion by the Company of Redx Pharma Plc in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

'It's a particularly exciting time for Redx Pharma' - Capital Network's...

Capital Network's Healthcare Analyst Riccardo Lowi gives his view on Redx Pharma Plc (LON:REDX). ''The reason it's a particularly exciting time for the company is because they're moving  their two lead candidates into the clinical stage, it's the first time they're moving a drug...

on 3/4/17

2 min read